

Yusuf Yilmaz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9344825/publications.pdf>

Version: 2024-02-01

119
papers

11,217
citations

81839

39
h-index

32815

100
g-index

120
all docs

120
docs citations

120
times ranked

10122
citing authors

#	ARTICLE	IF	CITATIONS
1	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. <i>Journal of Hepatology</i> , 2020, 73, 202-209.	1.8	2,171
2	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. <i>Gastroenterology</i> , 2020, 158, 1999-2014.e1.	0.6	1,840
3	Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2019, 69, 2672-2682.	3.6	1,203
4	Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 748-755.e3.	2.4	559
5	Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis. <i>PLoS Medicine</i> , 2014, 11, e1001680.	3.9	507
6	The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. <i>Hepatology International</i> , 2020, 14, 889-919.	1.9	422
7	FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 362-373.	3.7	411
8	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 60-78.	8.2	330
9	Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. <i>Gut</i> , 2022, 71, 1006-1019.	6.1	195
10	Apoptosis: why and how does it occur in biology?. <i>Cell Biochemistry and Function</i> , 2011, 29, 468-480.	1.4	180
11	Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. <i>World Journal of Gastroenterology</i> , 2007, 13, 837.	1.4	165
12	Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. <i>European Journal of Clinical Investigation</i> , 2010, 40, 887-892.	1.7	159
13	Global multi-stakeholder endorsement of the MAFLD definition. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 388-390.	3.7	135
14	The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. <i>Journal of Hepatology</i> , 2022, 76, 771-780.	1.8	114
15	Serum levels of omentin, chemerin and adiponin in patients with biopsy-proven nonalcoholic fatty liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2011, 46, 91-97.	0.6	107
16	Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1625-1633.e1.	2.4	107
17	Administrative Coding in Electronic Health Care Record-Based Research of NAFLD: An Expert Panel Consensus Statement. <i>Hepatology</i> , 2021, 74, 474-482.	3.6	102
18	Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: association with liver fibrosis. <i>Metabolism: Clinical and Experimental</i> , 2010, 59, 1327-1330.	1.5	93

#	ARTICLE	IF	CITATIONS
19	Coronary flow reserve is impaired in patients with nonalcoholic fatty liver disease: Association with liver fibrosis. <i>Atherosclerosis</i> , 2010, 211, 182-186.	0.4	84
20	Obesity-Associated Nonalcoholic Fatty Liver Disease. <i>Clinics in Liver Disease</i> , 2014, 18, 19-31.	1.0	75
21	Characterization of lean patients with nonalcoholic fatty liver disease: potential role of high hemoglobin levels. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 341-346.	0.6	74
22	Assessment of endothelial function in patients with nonalcoholic fatty liver disease. <i>Endocrine</i> , 2013, 43, 100-107.	1.1	72
23	Kefir Improves the Efficacy and Tolerability of Triple Therapy in Eradicating <i>Helicobacter pylori</i> . <i>Journal of Medicinal Food</i> , 2011, 14, 344-347.	0.8	70
24	Arterial stiffness in patients with non-alcoholic fatty liver disease is related to fibrosis stage and epicardial adipose tissue thickness. <i>Atherosclerosis</i> , 2014, 237, 490-493.	0.4	67
25	Serum levels of vaspin, obestatin, and apelin-36 in patients with nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2011, 60, 544-549.	1.5	61
26	Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease. <i>Clinical Biochemistry</i> , 2009, 42, 802-807.	0.8	58
27	Serum fetuin A and 2HS-glycoprotein levels in patients with non-alcoholic fatty liver disease: relation with liver fibrosis. <i>Annals of Clinical Biochemistry</i> , 2010, 47, 549-553.	0.8	56
28	Clinical Value of the Malnutrition-Inflammation-Atherosclerosis Syndrome for Long-Term Prediction of Cardiovascular Mortality in Patients with End-Stage Renal Disease: A 5-Year Prospective Study. <i>Nephron Clinical Practice</i> , 2008, 108, c99-c105.	2.3	53
29	Circulating vaspin levels and epicardial adipose tissue thickness are associated with impaired coronary flow reserve in patients with nonalcoholic fatty liver disease. <i>Atherosclerosis</i> , 2011, 217, 125-129.	0.4	53
30	Simple Noninvasive Scores Are Clinically Useful to Exclude, Not Predict, Advanced Fibrosis: A Study in Turkish Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease. <i>Gut and Liver</i> , 2020, 14, 486-491.	1.4	51
31	Liver disease and malnutrition. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2013, 27, 619-629.	1.0	50
32	A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1456-e1468.	2.4	49
33	Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 329-338.	0.7	49
34	NAFLD in the Absence of Metabolic Syndrome: Different Epidemiology, Pathogenetic Mechanisms, Risk Factors for Disease Progression?. <i>Seminars in Liver Disease</i> , 2012, 32, 014-021.	1.8	45
35	Cytokeratin-18 fragments and biomarkers of the metabolic syndrome in nonalcoholic steatohepatitis. <i>World Journal of Gastroenterology</i> , 2009, 15, 4387.	1.4	44
36	Serum Levels of Hepcidin in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease. <i>Metabolic Syndrome and Related Disorders</i> , 2011, 9, 287-290.	0.5	44

#	ARTICLE	IF	CITATIONS
37	Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease. <i>Clinical Biochemistry</i> , 2012, 45, 655-658.	0.8	43
38	A comparison of FibroMeter [®] , [†] NAFLD Score, NAFLD fibrosis score, and transient elastography as noninvasive diagnostic tools for hepatic fibrosis in patients with biopsy-proven non-alcoholic fatty liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2014, 49, 1343-1348.	0.6	43
39	Serum biomarkers of fibrosis and extracellular matrix remodeling in patients with nonalcoholic fatty liver disease: association with liver histology. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 43-46.	0.8	43
40	Serum concentrations of human angiopoietin-like protein 3 in patients with nonalcoholic fatty liver disease: association with insulin resistance. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 1247-1251.	0.8	41
41	Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver disease. <i>Acta Diabetologica</i> , 2020, 57, 613-618.	1.2	41
42	A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 345-352.	1.4	41
43	Serum concentrations of human insulin-like growth factor-1 and levels of insulin-like growth factor-binding protein-5 in patients with nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 255-261.	0.8	40
44	Serum osteocalcin levels in patients with nonalcoholic fatty liver disease: Association with ballooning degeneration. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2011, 71, 631-636.	0.6	39
45	Serum levels of osteoprotegerin in the spectrum of nonalcoholic fatty liver disease. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2010, 70, 541-546.	0.6	38
46	Characterization of nonalcoholic fatty liver disease unrelated to the metabolic syndrome. <i>European Journal of Clinical Investigation</i> , 2012, 42, 411-418.	1.7	37
47	Role of intensive dietary and lifestyle interventions in the treatment of lean nonalcoholic fatty liver disease patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1352-1357.	0.8	37
48	Comparison of noninvasive scores for the detection of advanced fibrosis in patients with nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 137-141.	0.8	36
49	Accuracy of Fibrosis-4 index and non-alcoholic fatty liver disease fibrosis scores in metabolic (dysfunction) associated fatty liver disease according to body mass index. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, Publish Ahead of Print, 98-103.	0.8	33
50	Noninvasive detection of hepatic steatosis in patients without ultrasonographic evidence of fatty liver using the controlled attenuation parameter evaluated with transient elastography. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 1330-1334.	0.8	32
51	Characterization of Patients with Biopsy-Proven Non-Alcoholic Fatty Liver Disease and Normal Aminotransferase Levels. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 427-431.	0.5	32
52	Detection of hepatic steatosis using the controlled attenuation parameter: a comparative study with liver biopsy. <i>Scandinavian Journal of Gastroenterology</i> , 2014, 49, 611-616.	0.6	31
53	Non-alcoholic fatty liver disease: A growing public health problem in Turkey. <i>Turkish Journal of Gastroenterology</i> , 2019, 30, 865-871.	0.4	30
54	Gallstone Disease Does Not Predict Liver Histology in Nonalcoholic Fatty Liver Disease. <i>Gut and Liver</i> , 2014, 8, 313-317.	1.4	28

#	ARTICLE	IF	CITATIONS
55	Effect of fluvastatin on serum prohepcidin levels in patients with end-stage renal disease. <i>Clinical Biochemistry</i> , 2008, 41, 1055-1058.	0.8	27
56	Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients. <i>Metabolism: Clinical and Experimental</i> , 2010, 59, 64-69.	1.5	25
57	The diagnostic utility of fibrosis-4 or nonalcoholic fatty liver disease fibrosis score combined with liver stiffness measurement by fibroscan in assessment of advanced liver fibrosis: a biopsy-proven nonalcoholic fatty liver disease study. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 642-649.	0.8	24
58	Serum Progranulin as an Independent Marker of Liver Fibrosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease. <i>Disease Markers</i> , 2011, 31, 205-210.	0.6	24
59	Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience. <i>Turkish Journal of Gastroenterology</i> , 2019, 30, 892-898.	0.4	24
60	The association of fatty pancreas with subclinical atherosclerosis in nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 411-417.	0.8	23
61	Nonalcoholic Fatty Liver Disease: A Nutritional Approach. <i>Metabolic Syndrome and Related Disorders</i> , 2012, 10, 161-166.	0.5	22
62	Nonalcoholic Steatohepatitis Score is an Independent Predictor of Right Ventricular Dysfunction in Patients with Nonalcoholic Fatty Liver Disease. <i>Cardiovascular Therapeutics</i> , 2015, 33, 294-299.	1.1	22
63	Serum osteopontin levels as a predictor of portal inflammation in patients with nonalcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2013, 45, 58-62.	0.4	21
64	Diagnostic usefulness of FibroMeter VCTE for hepatic fibrosis in patients with nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 1149-1153.	0.8	21
65	Is nonalcoholic fatty liver disease the hepatic expression of the metabolic syndrome?. <i>World Journal of Hepatology</i> , 2012, 4, 332.	0.8	20
66	Screening for hepatic fibrosis and steatosis in Turkish patients with type 2 diabetes mellitus: A transient elastography study. <i>Turkish Journal of Gastroenterology</i> , 2019, 30, 266-270.	0.4	20
67	Elevated serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) in patients with nonalcoholic steatohepatitis and chronic hepatitis C. <i>Medical Science Monitor</i> , 2009, 15, CR189-93.	0.5	20
68	Hepatic expression and serum levels of syndecan 1 (CD138) in patients with nonalcoholic fatty liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 1488-1493.	0.6	19
69	A "Biomarker Biopsy" for the Diagnosis of NASH: Promises from CK-18 Fragments. <i>Obesity Surgery</i> , 2008, 18, 1507-1508.	1.1	18
70	Prevalence of hepatic steatosis in apparently healthy medical students: a transient elastography study on the basis of a controlled attenuation parameter. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 1264-1267.	0.8	18
71	Not only type 2 diabetes but also prediabetes is associated with portal inflammation and fibrosis in patients with non-alcoholic fatty liver disease. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 328-331.	1.2	17
72	Serum M30 levels: A potential biomarker of severe liver disease in nonalcoholic fatty liver disease and normal aminotransferase levels. <i>Hepatology</i> , 2009, 49, 697-697.	3.6	16

#	ARTICLE	IF	CITATIONS
73	Identification of a support vector machine-based biomarker panel with high sensitivity and specificity for nonalcoholic steatohepatitis. <i>Clinica Chimica Acta</i> , 2012, 414, 154-157.	0.5	16
74	Proteomic analysis of serum in patients with non-alcoholic steatohepatitis using matrix-assisted laser desorption ionization time-of-flight mass spectrometry. <i>Scandinavian Journal of Gastroenterology</i> , 2009, 44, 1471-1476.	0.6	14
75	Cigarette smoking is not associated with specific histological features or severity of nonalcoholic fatty liver disease. <i>Hepatology</i> , 2010, 52, 391-391.	3.6	14
76	Serum pigment epithelium-derived factor levels are increased in patients with biopsy-proven nonalcoholic fatty liver disease and independently associated with liver steatosis. <i>Clinica Chimica Acta</i> , 2011, 412, 2296-2299.	0.5	14
77	Circulating Levels of Vascular Endothelial Growth Factor A and Its Soluble Receptor in Patients with Biopsy-proven Nonalcoholic Fatty Liver Disease. <i>Archives of Medical Research</i> , 2011, 42, 38-43.	1.5	14
78	acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study. <i>EClinicalMedicine</i> , 2021, 41, 101145.	3.2	14
79	Cytokeratins in hepatitis. <i>Clinica Chimica Acta</i> , 2011, 412, 2031-2036.	0.5	13
80	Serum zinc- α 2-glycoprotein concentrations in patients with non-alcoholic fatty liver disease. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 93-7.	1.4	13
81	Caspase-cleaved fragments of cytokeratin 18 in patients with chronic hepatitis B. <i>Clinica Chimica Acta</i> , 2010, 411, 2029-2032.	0.5	12
82	Serum proteomics for biomarker discovery in nonalcoholic fatty liver disease. <i>Clinica Chimica Acta</i> , 2012, 413, 1190-1193.	0.5	12
83	Arterial stiffness is associated independently with liver stiffness in biopsy-proven nonalcoholic fatty liver disease: a transient elastography study. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 54-57.	0.8	11
84	Biomarkers for Early Detection of Non-Alcoholic Steatohepatitis: Implications for Drug Development and Clinical Trials. <i>Current Drug Targets</i> , 2013, 14, 1357-1366.	1.0	11
85	Serial changes in circulating M30 antigen, a biomarker of apoptosis, in patients with acute coronary syndromes: relationship with the severity of coronary artery disease. <i>Coronary Artery Disease</i> , 2009, 20, 494-498.	0.3	10
86	Serum galectin-3 levels in patients with nonalcoholic fatty liver disease. <i>Clinical Biochemistry</i> , 2011, 44, 955-958.	0.8	10
87	Linking Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: From Bedside to Bench and Back. <i>Tumori</i> , 2013, 99, 10-16.	0.6	10
88	Measurements of serum procollagen-III peptide and M30 do not improve the diagnostic accuracy of transient elastography for the detection of hepatic fibrosis in patients with nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 667-671.	0.8	10
89	Impact of aerobic training with and without whole-body vibration training on metabolic features and quality of life in non-alcoholic fatty liver disease patients. <i>Annales D'Endocrinologie</i> , 2020, 81, 493-499.	0.6	9
90	Biomarkers for noninvasive biochemical diagnosis of nonalcoholic steatohepatitis: Tools or decorations?. <i>World Journal of Gastroenterology</i> , 2009, 15, 4346.	1.4	9

#	ARTICLE	IF	CITATIONS
91	Comparison of Doppler ultrasound and transient elastography in the diagnosis of significant fibrosis in patients with nonalcoholic steatohepatitis. <i>Abdominal Radiology</i> , 2016, 41, 1505-1510.	1.0	8
92	Potential clinical variants detected in mitochondrial DNA D-loop hypervariable region I of patients with non-alcoholic steatohepatitis. <i>Hormones</i> , 2019, 18, 463-475.	0.9	8
93	Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2015, 21, 8096.	1.4	8
94	A Bayesian approach to an integrated multimodal noninvasive diagnosis of definitive nonalcoholic steatohepatitis in the spectrum of nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 1292-1295.	0.8	7
95	Liver stiffness is associated with disease severity and worse clinical scenarios in coronavirus disease 2019: A prospective transient elastography study. <i>International Journal of Clinical Practice</i> , 2021, 75, e14363.	0.8	7
96	Concentrations of connective tissue growth factor in patients with nonalcoholic fatty liver disease: association with liver fibrosis. <i>Disease Markers</i> , 2012, 33, 77-83.	0.6	7
97	Letter: the use of Fibrosisâ€4 score in primary care and diabetology practicesâ€”Occamâ€™s razor applied to advanced fibrosis screening. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1759-1760.	1.9	7
98	Diagnostic Role of Colon Capsule Endoscopy in Patients with Optimal Colon Cleaning. <i>Gastroenterology Research and Practice</i> , 2016, 2016, 1-5.	0.7	5
99	The interaction between current smoking and hemoglobin on the risk of advanced fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 597-600.	0.8	5
100	Macro- and micronutrients in metabolic (dysfunction) associated fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, Publish Ahead of Print, .	0.8	5
101	Feasibility of Fibroscan in Assessment of Hepatic Steatosis and Fibrosis in Obese Patients: Report From a General Internal Medicine Clinic. , 2021, 32, 466-472.		5
102	The quest for liver fibrosis biomarkers: Promises from the enhanced liver fibrosis panel and beyond. <i>Hepatology</i> , 2009, 49, 1056-1057.	3.6	4
103	Apoptosis in nonalcoholic steatohepatitis with normal aminotransferase values: zooming in on cytokeratin 18 fragments. <i>Biomarkers in Medicine</i> , 2010, 4, 743-745.	0.6	4
104	Evaluation of the Impact of Metabolic Syndrome on Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease. , 2021, 32, 661-666.		4
105	The AGEs-RAGE axis and nonalcoholic steatohepatitis: the evidence mounts. <i>Journal of Gastroenterology</i> , 2010, 45, 782-783.	2.3	3
106	Is M65 really better than M30 as a biomarker of hepatic fibrosis?. <i>Hepatology</i> , 2012, 55, 654-654.	3.6	2
107	Hepatic fibrosis â€œ and not steatosis â€œ is the main determinant of arterial stiffness in non-alcoholic fatty liver disease. <i>Atherosclerosis</i> , 2019, 290, 222-223.	0.4	2
108	Letter: a stepwise approach towards the screening of hepatic fibrosis in the general population. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 669-670.	1.9	2

#	ARTICLE	IF	CITATIONS
109	Non-alcoholic Fatty Liver Disease: A Global Public Health Issue. , 2020, , 321-333.		2
110	â€œDefragmentingâ€•the noninvasive diagnosis of nonalcoholic steatohepatitis: Hopes from cytokeratin-18. Hepatology, 2009, 50, 990-991.	3.6	1
111	Reply to Aydin et al: â€œTo what extent is it right to measure serum vaspin, obestatin, and apelin-36 levels without a protease inhibitor in nonalcoholic fatty liver disease?â€• Metabolism: Clinical and Experimental, 2011, 60, e2.	1.5	1
112	Research update for articles published in EJCI in 2010. European Journal of Clinical Investigation, 2012, 42, 1149-1164.	1.7	1
113	NFS Is Not a Marker of Nonalcoholic Fatty Liver Disease Per Se: What Is the True Relationship With CAD Complexity?. Angiology, 2020, 71, 83-84.	0.8	1
114	Evaluation of spleen stiffness in healthy population: a vibration-controlled transient elastography study. Journal of Health Sciences and Medicine, 2022, 5, 689-692.	0.0	1
115	Commentary on â€œCytokeratin 18, a Marker of Cell Death, is Increased in Children With Suspected Nonalcoholic Fatty Liver Diseaseâ€• Journal of Pediatric Gastroenterology and Nutrition, 2009, 49, 371-371.	0.9	0
116	Molecular signatures of nonalcoholic fatty liver disease: The present and future. Hepatology, 2010, 51, 1866-1866.	3.6	0
117	Multimarker Strategies for Detecting NASH and NASH-Related Fibrosis: Promises and Caveats. Obesity Surgery, 2011, 21, 1316-1317.	1.1	0
118	Transient elastography for assessing severe hepatic fibrosis in diabetic patients with nonalcoholic fatty liver disease: definitions matter. European Journal of Gastroenterology and Hepatology, 2019, 31, 1601-1602.	0.8	0
119	Effect of carbon dioxide versus room air insufflation on post-colonoscopy pain: A prospective, randomized, controlled study. Turkish Journal of Gastroenterology, 2020, 31, 676-680.	0.4	0